Among the family of nootropic drugs, Coluracetam Nootropics(CAS 135463-81-9) is a unique and precisely targeted cetane derivative. Unlike traditional drugs such as piracetam and piracetam, it is not a broad-spectrum neuromodulator but a specific high-affinity choline uptake enhancer. It precisely targets the rate-limiting step in acetylcholine synthesis, becoming a core ingredient for repairing cholinergic neuronal damage, improving cognitive deficits, and regulating mood. Initially developed by Mitsubishi Tanabe Pharmaceutical Co., Ltd. in Japan for the treatment of Alzheimer's disease, it was later expanded by BrainCells Inc. to areas such as depression and cognitive impairment in schizophrenia. With its advantages of "repairing damaged neurons, long-lasting nootropic effects, and low toxicity and safety," it has become a research hotspot for pharmaceutical-grade nootropic ingredients.
Precise structure-property framework and physicochemical properties of heterocyclic fusion
Coluracetam Nootropics, chemically named N-(2,3-dimethyl-5,6,7,8-tetrahydrofurano[2,3-b]quinolin-4-yl)-2-(2-oxo-1-yl)acetamide, with the molecular formula C₁₉H₂₃N₃O₃ and a precise molecular weight of 341.40 Da, is one of the most structurally complex and highly specific nootropic drugs in the course of the cetam class. Its specific stereoconformity and well-defined structure-activity relationship form the structural basis for its targeting of the cholinergic system, high selectivity, and strong stability.
The tetrahydrofurano[2,3-b]quinoline core is the most distinctive structural module of Coluracetam Nootropics, consisting of a rigid heterocyclic skeleton formed by the fusion of a benzene ring, a piperidine ring, and a furan ring, with methyl groups at positions 2 and 3 and an amide bond at position 4. The structure-activity relationship of this module is reflected in three aspects: first, the rigid fused-ring structure endows the molecule with high stability, making it less susceptible to hydrolysis and oxidation by in vivo enzymes, thus extending its half-life; second, the 2,3-dimethyl substitution creates steric hindrance, preventing the molecule from binding to non-target receptors and enhancing its specificity; and third, the highly matched hydrophobic pocket of the active center of furanoquinoline provides a structural basis for targeted binding. Studies have confirmed that removing the 2,3-dimethyl group or disrupting the fused-ring structure results in a loss of over 90% of the enhanced HACU activity.
The molecule retains the 2-keto ring common to cetane drugs at its terminal end, linked by a methylene group to an amide bond. This side chain is an "essential group for nootropic activity": on the one hand, the amide carbonyl group of the keto ring forms a hydrogen bond with the polar head of neuronal membrane phospholipids, enhancing the molecule's transmembrane permeability and membrane retention; on the other hand, its spatial conformation is similar to that of traditional cetane drugs, retaining basic neuromodulatory activity, but due to the difference in the parent nucleus, it lacks the glutamate receptor regulatory effect of traditional cetane drugs, specifically focusing on the cholinergic system. Comparative experiments showed that replacing the ketone with morpholinone reduced nootropic activity by 75% and water solubility by 60%.
The core and side chain are connected by -NH-CO-CH₂-acetamide bonds. This structure combines rigidity and flexibility: the conjugated π electron system of the amide bond stabilizes the molecular conformation and prevents deformation of the active site; the flexible rotation of the methylene group allows the side chain to form an optimal angle with the core, enabling the molecule to simultaneously bind to two binding sites of choline transporters-the hydrophobic pocket of the core and the polar catalytic region of the side chain, achieving "dual-site binding." The activity is 5-8 times that of single-site binding of cetams.
In terms of quality control, pharmaceutical-grade Coluracetam Nootropics adheres to stringent international standards: HPLC purity ≥99.0%, trans configuration ≥99.9%, moisture ≤0.5%, residue on ignition ≤0.1%, and related substances comply with ICH Q3A requirements. Identification is performed using a triple verification method of infrared spectroscopy, nuclear magnetic resonance, and mass spectrometry, while content determination uses the HPLC external standard method to ensure batch-to-batch consistency and activity stability of the raw materials.
The triple repair mechanism regulated by specific cholinergic mechanisms
Acetylcholine is a core neurotransmitter for memory, learning, attention, and cognition. The rate-limiting step in its synthesis is high-affinity choline uptake-neurons use high-affinity choline transporters on the cell membrane to bring extracellular choline up into the cell against its concentration gradient, providing raw materials for ACh synthesis. Coluracetam's core mechanism is to specifically enhance ChT activity and accelerate the HACU process, which is its key differentiator from all other nootropic drugs:
Direct activation of ChT protein: Coluracetam Nootropics molecules precisely bind to the extracellular regulatory domain of ChT, inducing a conformational change in ChT, increasing its affinity for choline, and simultaneously increasing ChT expression on the cell membrane, resulting in a 5-10 fold increase in the choline uptake rate.
Selective action on damaged neurons: A key characteristic-Coluracetam Nootropics has a weak effect on enhancing HACU in healthy neurons, but a very strong effect on damaged, degenerated, and aging neurons. The mechanism involves abnormal phosphorylation levels and suppressed activity of ChT in damaged neurons. Coluracetam Nootropics can reverse this abnormal phosphorylation, restoring normal function and achieving the ideal effect of "precise repair without interfering with healthy neurons."
Long-lasting activation: After a single dose, the HACU-enhancing effect can last for more than 72 hours. Because Coluracetam Nootropics can induce upregulation of ChT gene expression, it forms a dual effect of "short-term activation + long-term expression," achieving long-lasting cognitive enhancement.
After HACU acceleration, intracellular choline concentration increases significantly, directly activating choline acetyltransferase, a key enzyme in ACh synthesis, increasing the ACh synthesis rate by 3-5 times and reversing ACh depletion caused by cholinergic deficiency. Simultaneously, Coluracetam Nootropics can:
- Enhance presynaptic ACh release: Increase the amount of ACh quanta released triggered by neuronal action potentials, increase ACh concentration in the synaptic cleft, and strengthen cholinergic neurotransmission.
- Repair cholinergic neuronal structure: Promote the synthesis of ChAT and vesicular acetylcholine transporters, repair damaged neuronal synaptic structure, increase synaptic density, and reconstruct cognitively relevant neural circuits.
- Inhibit ACh self-negative feedback: Mildly block presynaptic M2 cholinergic receptors, reduce ACh release inhibition, and further improve cholinergic transmission efficiency.
Coluracetam Nootropics not only increases ACh levels but also regulates downstream synaptic plasticity and neuroprotective signals through the cholinergic pathway, fundamentally improving cognition and delaying neurodegeneration:
- Activating AMPA receptor-mediated synaptic plasticity: Increased ACh levels activate α7 nicotinic cholinergic receptors, thereby promoting AMPA glutamate receptor membrane expression and phosphorylation, enhancing long-term potentiation (LTP)-a core cellular mechanism of learning and memory. Experiments show that Coluracetam Nootropics can increase hippocampal LTP amplitude by 60% and enhance synaptic transmission efficiency.
- Inhibiting neuroinflammation and oxidative stress: By activating the JAK2/STAT3 anti-inflammatory pathway through α7nAChR, it inhibits microglia activation, reduces the release of inflammatory oxidative factors such as TNF-α, IL-1β, and ROS, and protects neurons from inflammatory oxidative damage.
- Anti-neuronal apoptosis: Upregulates the expression of the anti-apoptotic protein Bcl-2, downregulates the activity of pro-apoptotic proteins Bax and caspase-3, inhibits the mitochondrial apoptosis pathway, and reduces the apoptosis rate of damaged neurons by 65%.
- Improves cerebral blood flow and energy metabolism: Enhances the cholinergic function of cerebral vascular endothelial cells, dilates cerebral microvessels, increases cerebral blood flow, increases glucose and oxygen uptake, and improves energy supply to cognitive brain regions.
Precisely targeted raw materials for cognitive repair and mental regulation
The core pathology of Alzheimer's disease (AD) is the degeneration of cholinergic neurons in the basal forebrain and a sharp decline in acetylcholine synthesis. Coluracetam Nootropics, by enhancing the HACU (hypochondral cholinergic chorionic villus ductus var. cholinergic chorionic villus ... Clinically used in patients with post-traumatic brain injury and memory loss, a daily dose of 160 mg for 8 weeks resulted in a 68% effective rate of memory recovery, superior to piracetam and with a faster onset of action.
One of the core symptoms of schizophrenia is prefrontal cholinergic dysfunction and cognitive decline. The PCP schizophrenia model demonstrated that Coluraracetam can reverse the deficiency of choline acetyltransferase in the medial septal nucleus, restoring prefrontal ACh levels to normal and improving attention deficit and working memory deficits. Phase II clinical trials showed that a daily dose of 200 mg for 12 weeks improved the MATRICS cognitive score by 4.1 points, significantly improving attention and verbal memory without affecting psychiatric symptoms.
Colluracetam demonstrates unique efficacy in treating SSRI-resistant major depression accompanied by anxiety and cognitive impairment. Phase II clinical trials showed that after 8 weeks of daily administration of 240mg, the HAM-D depression score decreased by 5.8 points, the HAM-A anxiety score decreased by 4.2 points, and the improvement rate of cognitive impairment, poor concentration, and memory decline reached 75%, with no side effects such as drowsiness or sexual dysfunction, providing a new target for the treatment of depression.
Coluracetam Nootropics can penetrate the blood-retinal barrier, protecting retinal ganglion cells and the optic nerve, and is used for the protection against ischemic retinopathy and optic nerve damage in glaucoma. In a rat model of retinal ischemia, administration increased retinal ganglion cell survival by 60%, reduced optic nerve axonal degeneration by 50%, and restored visual evoked potential amplitude to normal. Furthermore, it has a protective effect against diabetic peripheral neuropathy and chemotherapy-induced neurotoxicity, can repair peripheral nerve cholinergic function, and alleviate numbness and pain symptoms.
Some experiments and user feedback show that Coluracetam Nootropics can enhance cholinergic activity in the visual cortex, improve visual contrast and color saturation, producing a "high-definition vision" effect. The mechanism is related to enhanced ACh release in the visual pathway and improved neuronal signal transduction efficiency. Currently in the preclinical research stage, it holds promise for adjunctive treatment of visual dysfunction.
Coluracetam Nootropics' latest research directions: precision medicine, formulation innovation, and clinical expansion.
A recent 2025 study successfully resolved the crystal structure of the ChT-Coluracetam Nootropics complex, clarifying the binding sites: the Coluracetam core binds to the hydrophobic pocket of the ChT transmembrane region, while the side chain binds to the extracellular loop catalytic region, providing precise targets for structural optimization and activity enhancement. Based on this, a derivative designed with HACU showed a 2.3-fold increase in activity and higher selectivity.
The study revealed a complete signaling axis: "Coluracetam-ChT-HACU-ACh-α7nAChR-CREB-BDNF". ACh activates α7nAChR, promoting CREB transcription factor phosphorylation and upregulating brain-derived neurotrophic factor (BDNF) expression. BDNF further promotes neurogenesis and synaptic plasticity, achieving long-term cognitive improvement. Simultaneously, it was discovered that it can regulate neurally related microRNAs such as miR-132 and miR-21, participating in the epigenetic regulation of neural repair.
Recent research has found that Coluracetam Nootropics can regulate gut microbiota, promote the secretion of choline metabolites by the microbiota, indirectly increase choline levels in the brain, and form a "gut-brain cholinergic axis," providing a new mechanism for enhancing the efficacy of oral administration.
One of the core symptoms of ASD is cholinergic system developmental abnormalities and cognitive-social deficits. Preclinical studies have shown that Coluracitam can improve social withdrawal, repetitive behaviors, and cognitive impairment in ASD model mice. Phase II clinical trials have been initiated, with preliminary results showing a 35% improvement in social communication scores and good safety.
Parkinson's disease is often accompanied by deficiencies in both the cholinergic and dopaminergic systems. Coluracitam in combination with levodopa can improve cognitive decline and hallucinations in PDD patients. Phase II clinical trials showed that the combination therapy group improved cognitive scores by 4.5 points, superior to the monotherapy group.
Chemotherapy drugs cause cholinergic neuron damage, known as "chemotherapy brain." Phase III clinical trials showed that daily administration of 200 mg for 8 weeks achieved a 72% remission rate of CRCI symptoms and significantly improved quality of life.
Phase III clinical trials showed that combined topical eye drops and oral administration reduced the loss of optic nerve fiber layer thickness by 60% and slowed the progression of visual field defects, providing a new approach for glaucoma neuroprotection.
Conclusion
Coluracetam Nootropics, a "mechanistic innovator" among cetirizine-based nootropic drugs, boasts a precise molecular structure with a trans-tetrahydrofuranoquinoline core, pyrrolidone side chain, and acetamide linker. Its unique mechanism of specifically enhancing high-affinity choline uptake, targeting and repairing damaged cholinergic neurons, long-lastingly increasing acetylcholine synthesis, and multi-dimensionally regulating synaptic plasticity and neuroprotection breaks through the bottleneck of traditional nootropic drugs' "broad spectrum, low efficacy, and significant side effects," becoming a core pharmaceutical ingredient in the fields of cognitive impairment repair, treatment-resistant depression, and neuroprotection. From the clinical treatment of Alzheimer's disease and vascular dementia to the precise intervention of cognitive deficits in schizophrenia and treatment-resistant depression, and the health maintenance of stress-induced cognitive decline and chemotherapy-induced brain damage, Coluracetam Nootropics redefines the value standard of cholinergic nootropic drugs with its core advantages of "high selectivity, strong repair capacity, low toxicity, long-lasting effect, and precise targeting."
Despite challenges such as poor water solubility, low bioavailability, and high synthesis costs, these bottlenecks are being overcome one by one with continuous breakthroughs in green synthesis processes, nanodelivery systems, crystal structure optimization, and precision clinical research. The application boundaries of Coluracetam Nootropics are constantly expanding-from single cognitive enhancement to full coverage of neurodegenerative diseases, mental illnesses, and nerve injury protection.
We welcome your requests for samples and look forward to supporting your research with reliable, high-quality Coluracetam Nootropics.
If you are interested in our products, have any criticisms or suggestions regarding our articles, or are not entirely satisfied with the products you have received, please also contact us by email: allen@faithfulbio.com; our team is dedicated to ensuring complete customer satisfaction.
References
- APExBIO. (n.d.). Coluracetam Nootropics (B1158). Retrieved April 13, 2026.
- PeptideDB. (n.d.). Coluracetam Nootropics (CAS 135463-81-9). Retrieved April 13, 2026.
- AbMole BioScience. (n.d.). Coluracetam Nootropics (M8892). Retrieved April 13, 2026.
- InvivoChem. (n.d.). Coluracetam Nootropics (V4076). Retrieved April 13, 2026.
- TargetMol. (n.d.). Coluracetam Nootropics (T7591). Retrieved April 13, 2026.
- Aladdin Scientific. (n.d.). Coluracetam Nootropics (C190679). Retrieved April 13, 2026.
- 10xchem.com. (n.d.). Coluracetam Nootropics (TX009DGA). Retrieved April 13, 2026.
- TargetMol. (n.d.). Coluracetam Nootropics (T7591) - Chinese. Retrieved April 13, 2026.